The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), in their consensus report, highlight the use of GLP1-RAs, especially in patients with T2DM who have established atherosclerotic CVD, heart failure, or chronic kidney disease, given their proven benefit in reducing major adverse CV events (MACE) [121]. This evidence concerns the gene GCG and type 2 diabetes mellitus.